PHARMANUTRA S.P.A.
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It also offers iron deficien… Read more
PHARMANUTRA S.P.A. (761) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PHARMANUTRA S.P.A. (761) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PHARMANUTRA S.P.A. - Net Assets Trend (None–None)
This chart illustrates how PHARMANUTRA S.P.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PHARMANUTRA S.P.A. (None–None)
The table below shows the annual net assets of PHARMANUTRA S.P.A. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PHARMANUTRA S.P.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PHARMANUTRA S.P.A. Competitors by Market Cap
The table below lists competitors of PHARMANUTRA S.P.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
YALLA GROUP SP.ADS/1 CL.A
F:80Q
|
$292.75 Million |
|
PWR Holdings Limited
PINK:PWRHF
|
$292.78 Million |
|
PetroVietnam Power Nhon Trach 2 JSC
VN:NT2
|
$292.79 Million |
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
$292.85 Million |
|
Baotou Dongbao Bio-Tech Co Ltd
SHE:300239
|
$292.71 Million |
|
Gedik Yatirim Menkul Degerler AS
IS:GEDIK
|
$292.68 Million |
|
Whirlpool of India Limited
NSE:WHIRLPOOL
|
$292.66 Million |
|
Hubei Biocause Heilen Pharmaceutical Co. Ltd.
SHE:301211
|
$292.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PHARMANUTRA S.P.A.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PHARMANUTRA S.P.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PHARMANUTRA S.P.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PHARMANUTRA S.P.A.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PHARMANUTRA S.P.A. (761) | €- | N/A | N/A | $292.74 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |